- |||||||||| GSK4527226 / GSK
Repeat IV and SC Dosing of the Anti-Sortilin Antibody AL101 (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2708;
Conclusions Repeat IV or SC administration of AL101 is generally safe and well tolerated. AL101 is a potent modulator of PGRN levels in the CSF, with a PK/PD profile that supports its further development in neurodegenerative diseases.
- |||||||||| GSK4527226 / GSK
REPEAT IV AND SC DOSING OF THE ANTISORTILIN ANTIBODY AL101 () - Oct 5, 2022 - Abstract #CTAD2022CTAD_40;
Multiple IV or SC administration of AL101 is generally safe and well tolerated in healthy volunteers. AL101 is a potent modulator of PGRN levels in the CSF, with a PK/PD profile that supports its further development in chronic neurological conditions such as Alzheimer’s and Parkinson’s disease.
- |||||||||| GSK4527226 / GSK
Trial completion, Trial completion date: A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 (clinicaltrials.gov) - Aug 10, 2022
P1, N=88, Completed,
AL101 is a potent modulator of PGRN levels in the CSF, with a PK/PD profile that supports its further development in chronic neurological conditions such as Alzheimer’s and Parkinson’s disease. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Jun 2022
- |||||||||| AL101 / GSK
A First-in-Human Study of the Anti-Sortilin Antibody AL101 (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3433;
AL101 was generally safe and well tolerated with single-dose IV or SC administration in healthy volunteers. AL101 is a potent modulator of PGRN levels in the CSF, with a PK/PD profile that supports development of SC AL101 in chronic conditions.
- |||||||||| GSK4527226 / GSK
Enrollment change, Trial completion date, Trial primary completion date: A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 (clinicaltrials.gov) - Jan 9, 2022
P1, N=79, Recruiting,
AL101 is being developed for the treatment of Alzheimer's Disease and Parkinson's Disease. N=53 --> 79 | Trial completion date: Oct 2021 --> Sep 2022 | Trial primary completion date: Aug 2021 --> Jun 2022
- |||||||||| AL101 / GSK
A First-in-human Study of the anti-Sortilin antibody AL101 () - Aug 7, 2021 - Abstract #CTAD2021CTAD_159;
AL101 has been generally safe and well tolerated with single-dose IV or SC administration in healthy volunteers. AL101 is a potent modulator of PGRN levels in the CSF, with a PK/PD profile that supports development of SC AL101 in chronic conditions.
- |||||||||| GSK4527226 / GSK
Trial completion date, Trial primary completion date: A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 (clinicaltrials.gov) - Feb 25, 2021
P1, N=53, Recruiting,
AL101 is a potent modulator of PGRN levels in the CSF, with a PK/PD profile that supports development of SC AL101 in chronic conditions. Trial completion date: Mar 2021 --> Oct 2021 | Trial primary completion date: Jan 2021 --> Aug 2021
- |||||||||| nirogacestat (PF-03084014) / SpringWorks Therap
Journal: Precision medicine for human cancers with Notch signaling dysregulation (Review). (Pubmed Central) - Sep 13, 2020
Small‑molecule γ‑secretase inhibitors (AL101, MRK‑560, nirogacestat and others) and antibody‑based biologics targeting Notch ligands or receptors [ABT‑165, AMG 119, rovalpituzumab tesirine (Rova‑T) and others] have been developed as investigational drugs...Phase III clinical trials of Rova‑T for patients with small‑cell lung cancer and a phase III clinical trial of nirogacestat for patients with desmoid tumors are ongoing. Integration of human intelligence, cognitive computing and explainable artificial intelligence is necessary to construct a Notch‑related knowledge‑base and optimize Notch‑targeted therapy for patients with cancer.
- |||||||||| GSK4527226 / GSK
Enrollment open, Trial completion date: A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 (clinicaltrials.gov) - Jul 22, 2020
P1, N=42, Recruiting,
Integration of human intelligence, cognitive computing and explainable artificial intelligence is necessary to construct a Notch‑related knowledge‑base and optimize Notch‑targeted therapy for patients with cancer. Not yet recruiting --> Recruiting | Trial completion date: Sep 2020 --> Jan 2021
|
